Reactive astrocytes promote adhesive interactions between brain endothelium and endothelial progenitor cells via HMGB1 and beta-2 integrin signaling

Kazuhide Hayakawa*, Loc-Duyen D. Pham, Ken Arai, Eng H. Lo*

Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital, Charlestown, MA, USA
Harvard Medical School, USA

Received 10 August 2013; received in revised form 18 December 2013; accepted 21 December 2013
Available online 29 December 2013

Abstract Endothelial progenitor cells (EPCs) may contribute to neurovascular repair after stroke and neurodegeneration. A key step in this process should involve adhesive interactions between EPCs and the targeted cerebral endothelium. Here, we tested the hypothesis that reactive astrocytes may play a critical role in enhancing adhesive interactions and transmigration of EPCs across cerebral endothelial cells. Transiently seeding EPCs onto a monolayer of RBE.4 rat brain endothelial cells resulted in a time-dependent adherence between the two cell types. Blocking β2 integrins on EPCs or blocking the receptor for advanced glycation endproducts (RAGE) on endothelial cells significantly decreased EPC-endothelial adherence. Next, we tested whether reactive astrocytes can enhance this process by growing EPCs, brain endothelial cells and astrocytes together in a transwell co-culture system. The presence of reactive astrocytes in the lower chamber significantly promoted adherence between EPCs and endothelial cells in the upper chamber. This process involved the release of soluble HMGB1 from reactive astrocytes that then upregulated endothelial expression of RAGE via Egr1 signaling. Directly adding HMGB1 to the transwell system also promoted EPC-endothelial adhesion and accelerated EPC transmigration into the lower chamber. These initial findings provide proof-of-concept that reactive astrocytes promote crosstalk between cerebral endothelium and EPCs. Further investigation of this phenomenon may lead to a better understanding of cell–cell interactions required for neurovascular recovery after stroke.

© 2013 The Authors. Published by Elsevier B.V. All rights reserved.

Introduction

For many years, CNS was considered to be an isolated and immune-privileged organ. However, it is now recognized that systemic responses in blood contribute to bi-directional signaling with the CNS after injury. Integrated responses in neurons, glia, brain blood vessels, and circulating peripheral cells all contribute to the pathogenesis of injury and
mechanisms of repair after stroke and trauma (Moskowitz et al., 2010).

A specific set of peripheral cells that have been implicated comprise the population of circulating endothelial progenitor cells (EPCs). EPCs have been viewed as adult stem cells that can play an important role in tissue vascularization and endothelium homeostasis after CNS damage and neurodegeneration (Rouhl et al., 2008; Nan et al., 2005). EPCs are highly migratory and may be attracted to injured or diseased brain areas, where they are thought to mediate angiogenesis, vasculogenesis and neurovascular tissue repair (Fan et al., 2010; Sobrino et al., 2007). The underlying mechanisms are not fully understood, and many potential mediators continue to be investigated, including "homing signals" such as stromal cell-derived factor-1 (SDF-1) (Lapidot, 2001) and "cell–cell interactive signals" such as β1- and β2- integrins (Shyu et al., 2006; Chavakis et al., 2005). However, what tends to be missing from these previous models is the consideration of cross-talk signals from other cells in the brain.

We recently showed that, by acting as sensors of neurovascular injury, astrocytes could augment EPC-mediated neurovascular remodeling after stroke and brain injury (Hayakawa et al., 2012, 2013). But what are the molecular mechanisms that underlie this ability of astrocytes to promote EPC function during CNS repair? In the present study, we examined the hypothesis that reactive astrocytes can release HMGB1, a member of the damage-associated-molecular-pattern (DAMP) family of proteins that subsequently enhances adhesive interactions and increases transmigration of EPCs across targeted brain endothelium.

Methods

All experiments were performed following an institutionally approved protocol in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Chemicals

Rat recombinant IL-1β and human recombinant HMGB1 were purchased from Sigma-Aldrich.

Antibodies

CD34, Flk-1 (VEGFR2) and Egr1 antibodies, control goat IgG and mouse IgG were purchased from Santa Cruz Biotechnology. RAGE antibody was purchased from R&D Systems. HMGB1 antibody (Abcam) and integrin antibodies (CD11a, CD11b, and CD18, BD biosciences) were purchased from each company. Antibodies against RAGE, CD11a, CD11b, and CD18 have neutralizing capacity.

Cell cultures

Rat brain endothelial cells

A rat brain microendothelial cell line, RBE.4 were maintained in EBM-2 containing EGM-2MV SingleQuots kit onto collagen-coated 25 cm² flasks at a density of 2 × 10⁵ cells/cm² incubated in a 5% CO₂ incubator at 37 °C. RBE.4 was dissociated by trypsinization and then reseeded on collagen I-coated 24 well plates for cell adhesion assay.

Rat endothelial progenitor cells

Spleens were used for the obtaining of EPCs as described as before (Rossell et al., 2009). For each independent experiment, spleens from 11 to 12 week old Sprague–Dawley (SD) rats were kept in PBS solution. Under the hood, spleens were mechanically minced, placed at 37 °C for 15 min in EPCs lysis buffer and run through a 40-μm nylon membrane to obtain cell suspension. Mononuclear cells (MNCs) were obtained by density gradient centrifugation with Ficoll-Paque Plus (Amersham Biosciences Corp). Isolated MNCs were shortly washed with red blood cells lysis solution and gently washed twice with complete growth media EGM-2MV (Lonza). MNCs were finally resuspended in EGM-2MV and 3 × 10⁷ MNCs per well were seeded on collagen I-coated six-well plates (Becton Dickinson Labware) and incubated in a 5% CO₂ incubator at 37 °C. Under daily observation, first media change was performed 3–4 days after plating. Early EPCs were used for each independent experiment between 5 and 7 days after seeding.

Primary astrocyte cultures

Primary astrocyte cultures were prepared from cerebral cortices of 2-day-old neonatal Sprague–Dawley rats as described as before (Arai et al., 2003). Briefly, dissociated cortical cells were suspended in Dulbecco's modified Eagle medium (NB, Life Technology) containing 25 mM glucose, 4 mM glutamine, 1 mM sodium pyruvate, and 10% fetal bovine serum and plated on uncoated 25 cm² flasks at a density of 6 × 10⁵ cells/cm². Monolayers of type 1 astrocytes were obtained 12–14 days after plating. Non-astrocytic cells such as microglia and neurons were detached from the flasks by shaking and removed by changing the medium. Astrocytes were dissociated by trypsinization and then reseeded on uncoated 6- and 24-well plates at a density of 1 × 10⁵ cells/cm².

Primary monocytes/macrophages cultures

Monocytes/macrophages were isolated from rat peritoneal cavity. After collecting cells from the cavity, 1 × 10⁵ cells per well were seeded on non-coated six-well plates and grown in RPMI medium 1640 containing 10% FBS, 1% penicillin/streptomycin. Twenty four hours later, attached cells were used as a mix of monocytes/macrophages.

EPCs labeling

Cells were incubated with 5 μg/ml 1, 1-dioctadecyl-3, 3, 3-tetramethylindocarbocyanine perchlorate (DiI)-labeled acetylated low density lipoprotein (ac-LDL; Molecular Probes) at 37 °C for 120 min in EGM-2 MV.

Monocytes/macrophages labeling

Cells were incubated with 3 μM calcein AM at 37 °C for 30 min in RPMI medium 1640 containing 10% FBS, 1% penicillin/streptomycin.
Cell adhesion assay

After 24 hours incubation with or without IL-1β (1, 10, and 100 ng/ml), ac-LDL labeled EPCs (1 × 10⁴ cells/well) were coincubated with RBE.4 monolayer at 37 °C for 10, 30, 60 and 90 min. Calcein AM-labeled monocytes/macrophages (1 × 10⁵ cells/well) were coincubated with RBE.4 monolayer 37 °C for 20 min. Then, adhered EPCs or monocytes/macrophages were fixed with 4% paraformaldehyde for 10 min and were washed three times with ice-cold phosphate-buffered saline (PBS) to remove non adherent cells. The numbers of adhered cells were quantified by counting the number of ac-LDL positive cells or calcein AM positive cells.

In vitro trans-endothelial migration assay

Rat brain endothelial cells (RBE.4) (1 × 10⁵ cells/well) were seeded on polycarbonate membrane (3-µm pore filters, Corning Costar) coated with collagen I to obtain confluent endothelial monolayers. Ac LDL-labeled EPCs (1 × 10⁵ cells/well) were placed in the upper chamber on top of the RBE.4 monolayer. The chambers were placed in a 24-well culture plate containing IL-1β (1 ng/ml) or recombinant HMGB1 (10 ng/ml) or rat cortical astrocytes. After 24 h of incubation at 37 °C, the lower side of the filter was washed with PBS and fixed with 4% PFA. Labeled EPCs migrating into the lower chamber were directly counted in 4 random microscopic fields.

Western blot analysis

Cultures were rinsed twice with PBS and cell membrane extracts were collected according to the method of ProteoExtract Kit (Calbiochem). Samples were heated with equal volumes of SDS sample buffer (Novex) and 10% 2-mercaptoethanol at 95 °C for 5 min, and then each sample was loaded onto 4–20% Tris-glycine gels. After electrophoresis and transferring to polyvinylidene difluoride membranes (Novex), the membranes were blocked in Tris-buffered saline containing 0.1% Tween 20 and 0.2% I-block (Tropix) for 60 min at 4 °C. Membranes were then incubated overnight at 4 °C with primary antibodies. After incubation with peroxidase-conjugated secondary antibodies, chemiluminescence was enhanced (GE Healthcare). Optical density was assessed using the NIH Image analysis software.

Immunohistochemistry

Cells were washed with ice-cold PBS (pH 7.4), followed by 4% paraformaldehyde for 10 min. After being washed three times in PBS containing 0.1% Triton X-100, they were incubated with 3% bovine serum albumin (BSA) in PBS for 1 h. Then cells were incubated with primary antibodies at 4 °C overnight. After washing with PBS, they were incubated with secondary antibodies (1:400; Jackson ImmunoResearch) for 1 h at room temperature. Finally, nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI), and coverslips were placed. Immunostaining was analyzed with a fluorescence microscope (Olympus BX51) interfaced with a digital charge-coupled device camera and an image analysis system.

Egr1 siRNA transfection in rat brain endothelial cells

Control siRNA and Egr1 siRNA were obtained from Santa Cruz Biotechnology. Control siRNA (sc37007) consists of a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Egr1 siRNA (sc270177) is a pool of 3 target-specific 19-25nt siRNAs designed to knock down gene expression. The sequences for rat Egr1 siRNAs are designed as followed; Sequence 1: 5′-CAGCCGUUUCAAUCCUUAAtt-3′, Sequence 2: 5′-CCAUUCCAGCAUCUAtt-3′, Sequence 3: 5′-UCUCCUAUCCUUAUCAAtt-3′. siRNAs were prepared according to the transfection protocol for cell cultures from Santa Cruz Biotechnology. Briefly, siRNA transfection reagent mixture of 1 ml (Transfection reagent, sc-29528, Transfection medium, sc36868) was co-incubated with RBE.4 for 6 h in a 5% CO₂ incubator at 37 °C, and then same amount of EBM-2 1% FBS was added. An additional incubation was performed for 18 h, and then the procedure for conditioned media was carried on.

Statistical analysis

All of experiments were blinded and performed in duplicate, repeated 3–5 times independently. GraphPad Prism 5 was used overall statistical analysis in this study. Results were expressed as mean ± SD. When only two groups were compared, Student’s t-test was used. Multiple comparisons were evaluated by Tukey’s test after one-way ANOVA or two-way ANOVA. P < 0.05 was considered to be statistically significant.

Results

EPC-endothelial adherence is mediated via β2-integrin-RAGE interactions

After isolation from rat spleen, early EPCs were positive for representative markers including Flk1 and CD34 at 5 days after seeding (Fig. 1a). Adhesion of diI-ac-LDL-labeled EPCs was assessed by counting labeled cells that remain attached after a transient co-incubation onto a monolayer of RBE.4 rat brain endothelial cells (Fig. 1b–c). When EPCs were stimulated with low concentrations of IL-1β for 24 h prior to incubation, adherence was significantly increased (Fig. 1c–d). Immunocytochemistry and western blots suggested that the increased adherence may be due to an IL-1β-induced upregulation of β2-integrin expression in EPCs (Fig. 2a–b). Blockade with anti-CD18 (β2-integrin) antibodies in EPCs decreased their adhesion to the endothelial monolayer (Fig. 2c). Conversely, adding an anti-RAGE antibody onto the RBE.4 endothelial cells also decreased EPC adhesion (Fig. 2d). Taken together, these data suggest that RAGE on endothelial cells binds β2-integrin on EPCs, thus facilitating their adhesive interactions.

Reactive astrocytes enhance EPC adherence via HMGB1-induced upregulation of endothelial RAGE

Astrocytes were stimulated with IL-1β, and as expected, this standard method yielded reactive astrocytes with elevated
expression of GFAP and vimentin (Fig. 3a), and promoted the release of HMGB1 into the conditioned media (Fig. 3b). Quantitation revealed that IL-1β-stimulated astrocytes released approximately 1–2 ng/ml of HMGB1. To ascertain whether reactive astrocytes can augment adhesion of EPCs onto RBE.4 endothelial cells, a triple-culture was performed with a transwell co-culture system (Fig. 3c). When reactive astrocytes were grown in the lower chamber, adhesion of EPCs onto endothelial cells was significantly increased in the upper chamber (Fig. 3d). To check the specificity of this phenomenon, monocytes/macrophages were also used in a triple-culture model (Fig. 3e). IL-1β itself enhanced adhesive interactions between monocytes/macrophages on endothelial cells but cell adherence was not significantly augmented by the presence of IL-1β-stimulated astrocytes in the lower chamber (Fig. 3f). Next, the role of astrocytic HMGB1 was tested by removing astrocytes from the transwell system completely and adding exogenous HMGB1 (0.1, 1, 10 ng/ml) into the lower chamber instead (Fig. 4a). This range of exogenous HMGB1 was chosen based on the levels of HMGB1 released by stimulated astrocytes. HMGB1 directly promoted adhesion between EPCs and the RBE.4 endothelial cells in the upper chamber (Fig. 4b). This effect may be mediated in part by the ability of HMGB1 to upregulate RAGE levels in the endothelial monolayer over time (Fig. 4c). HMGB1-induced upregulation of endothelial RAGE was dependent on Egr1, which is known to activate key promoter regions on the RAGE gene (Fig. 5a). When siRNA was used to suppress Egr1 signaling (Fig. 5b), the ability of HMGB1 to upregulate RAGE levels in the endothelial monolayer over time (Fig. 4c). HMGB1-induced upregulation of endothelial RAGE was dependent on Egr1, which is known to activate key promoter regions on the RAGE gene (Fig. 5a). When siRNA was used to suppress Egr1 signaling (Fig. 5b), the ability of HMGB1 to upregulate RAGE levels in the endothelial monolayer over time (Fig. 5a). When siRNA was used to suppress Egr1 signaling (Fig. 5b), the ability of HMGB1 to upregulate RAGE levels in the endothelial monolayer over time (Fig. 5a). When siRNA was used to suppress Egr1 signaling (Fig. 5b), the ability of HMGB1 to upregulate RAGE levels in the endothelial monolayer over time (Fig. 5a). When siRNA was used to suppress Egr1 signaling (Fig. 5b), the ability of HMGB1 to upregulate RAGE levels in the endothelial monolayer over time

**Figure 1** IL-1β-stimulated EPCs was enhanced the adhesive interaction to brain endothelial cells. (a) Early EPCs (5 days after seeding) were identified by representative markers including Flk1 and CD34. (b) Ac-LDL labeled EPCs adhered to rat brain endothelial cells (RBE.4). (c) The number of attached EPCs to RBE.4 monolayer was increased in a time-dependent manner and IL-1β (10 ng/ml)-stimulated EPCs showed more adherent ability to endothelial monolayer. *P < 0.05, **P < 0.01 vs normal EPCs. (d) Low concentration of IL-1β (1 and 10 ng/ml) stimulated EPCs and significantly augmented their adhesive interaction with endothelium. *P < 0.05 vs normal EPCs.

**Figure 2** IL-1β enhanced adhesive interaction between β2-integrin in EPCs and endothelium RAGE. (a) Immunocytochemistry showed enhancement of β2-integrin expression in EPCs after treatment with IL-1β (10 ng/ml). (b) Western blot analysis confirmed accumulation of β2-integrin in EPCs membrane. (c) Blocking with anti-CD18 (β2-integrin) antibody in EPCs significantly decreased their adhesion, but anti-CD11a blockade had no effects. *P < 0.05 vs normal EPCs adherence, **P < 0.05 vs IL-1β-stimulated EPCs adherence. These data support the idea that β2-integrin on EPCs are involved in adhesion. (d) Conversely, blocking with an anti-RAGE antibody in RBE.4 also decreased EPC adhesion. *P < 0.01 vs normal EPCs adherence, **P < 0.01 vs IL-1β-stimulated EPCs adherence.
Reactive astrocytes promote EPC-endothelial adhesion via HMGB1 and β-2 integrin signaling

EPC adherence on endothelial monolayers after HMGB1 stimulation (Fig. 5d–e).

Reactive astrocytes enhance EPC transmigration

After EPCs adhere onto endothelial cells, they may also transmigrate. Hence, we asked whether reactive astrocytes could also promote EPC transmigration in our transwell culture system (Fig. 6a). When IL-1β-stimulated reactive astrocytes were present in the lower chamber, dil-ac-LDL-labeled EPCs were able to adhere and then after 24 h, transmigrate across the RBE.4 brain endothelial monolayer growing in the upper chamber (Fig. 6b–c). In the absence of astrocytes, EPC transmigration across the endothelial monolayer was also induced by directly adding exogenous HMGB1 into the empty lower chamber (Fig. 6d).

Discussion

Our study provides in vitro proof-of-concept that reactive astrocytes play a key role in promoting EPC-brain endothelial adherence and transmigration. Our overall findings

Figure 3 Reactive astrocytic HMGB1 enhanced EPCs adherence to RBE.4 monolayer. (a) Western blot analysis showed that IL-1β increased reactive astrocytes markers (GFAP and vimentin) in a concentration-dependent manner. (b) Lower concentration of IL-1β (0.1 and 1 ng/ml) induced the release of HMGB1 in astrocytes as described as before (Hayakawa et al., 2010b). *P < 0.05 vs IL1β 0 ng/ml. (c) Co-culture between rat cortical astrocytes in the lower chamber and rat brain endothelial cells in the upper chamber was performed for 24 h. Then, labeled EPCs were added into the upper chamber for 45 min. (d) IL-1β (1 ng/ml)-stimulated reactive astrocytes enhanced EPCs adherence to RBE.4 monolayer. **P < 0.01 vs control group. (e) Calcein AM-labeled monocytes/macroages were added into the upper chamber for 20 min. (f) IL-1β (1 ng/ml) itself increased adhesive interaction of monocytes/macroanges. IL-1β-stimulated reactive astrocytes (IL-1β-A) did not enhance monocytes/macroanges adherence to RBE.4 monolayer. A: astrocytes.

Figure 4 Soluble HMGB1 promoted EPCs adherence through up-regulation of endothelium RAGE expression. (a) RBE.4 monolayer was prepared onto collagen I-coated transwell and HMGB1 (10 ng/ml) was added into the lower chamber for 24 h. (b) HMGB1 significantly induced more adhesive interaction between EPCs and endothelium. **P < 0.01 vs control group. (c) Treatment with HMGB1 in the lower chamber increased endothelium RAGE expression in a concentration-dependent manner. *P < 0.05 vs HMGB1 0 ng/ml.
demonstrate that (i) β2 integrin-RAGE interactions, (ii) reactive astrocytes release HMGB1 that promotes EPCs adherence but not monocytes/macrophages adherence by upregulating RAGE receptors on brain endothelial cells, and (iii) after adherence, HMGB1 also promotes EPC transmigration across brain endothelial monolayers. Hence, EPC

![Figure 5](image_url)

**Figure 5**  
Egr1 signaling pathway supports endothelium RAGE expression and EPCs adherence. (a) Western blot analysis showed that HMGB1 (10 ng/ml) significantly increased Egr-1 expression in RBE.4 in a time-dependent manner. *P < 0.05 vs HMGB1 0 min. (b) Egr-1 siRNA transfection successfully reduced Egr-1 expression induced by HMGB1 (10 ng/ml) after 60 min. (c) Rat brain endothelium RAGE expression 24 h after HMGB1 (10 ng/ml) stimulation significantly attenuated by Egr-1 siRNA transfection. *P < 0.05 vs control siRNA without HMGB1 stimulation. (d) RBE.4 monolayer treated with Egr-1 siRNA or control siRNA was prepared onto collagen I-coated transwell. Recombinant HMGB1 was added into the lower chamber for 24 h. Then, labeled EPCs were added into the upper chamber for 45 min. (e) Egr-1 siRNA transfection significantly reduced EPCs adherence rate. *P < 0.05 vs control siRNA-treated group.

![Figure 6](image_url)

**Figure 6**  
HMGB1 induced trans-endothelial migration of early EPCs. (a) Rat brain endothelial cells (RBE.4) monolayer was prepared onto the upper chamber. After adding recombinant IL-1β protein in rat cortical astrocytes in the lower chamber, labeled EPCs migration was allowed for 24 h. (b) Representative images of the trans-endothelial migration of diI-ac LDL labeled EPCs (red). Nuclear are indicated by DAPI. (c) IL-1β-stimulated astrocytes strongly attracted EPCs compared with normal astrocytes or IL-1β. *P < 0.05, **P < 0.01 (d) Data analysis showed that HMGB1 (10 ng/ml) itself enhanced trans-endothelial migration in early EPCs. *P < 0.05.
targeting in the brain may require a well-regulated set of cell–cell signals at the neurovascular interface.

EPCs are well known to play a major role in the pathology of diverse vascular disorders, including traumatic brain injury and stroke. The beneficial effects of EPCs have been described in rat models of focal cerebral ischemia (Fan et al., 2010; Taguchi et al., 2004). In humans, circulating levels of EPCs tend to track the temporal profile of recovery from 7 to 14 days after stroke onset (Navarro-Sobrino et al., 2010, 2011). More recently, soluble factors secreted from EPCs such as VEGF, FGF-beta, and PDGF-BB may be considered as positive mediators to promote angiogenesis and neurogenesis after stroke (Rosell et al., 2013). Although the therapeutic potential of EPCs in stroke has been suggested, it remains unclear how EPCs target the central nervous system. Our present findings may now provide a mechanism that directly links central crosstalk between reactive astrocytes and brain endothelial cells with a peripheral response in the systemic EPC response. Further dissection of these molecular pathways may lead to therapeutic approaches to potentially amplify these potentially beneficial EPC responses in damaged or diseased brain.

RAGE expression usually is low under normal condition but enhanced expression of RAGE has been observed in diabetic vasculature and other inflammatory diseases (Huttunen et al., 2002; Hori et al., 1995; Bierhaus et al., 2005). RAGE is not only involved in the regulation of cellular activation, but also functions as an adhesion receptor on endothelial cells. Enhancement of RAGE expression can promote the recruitment of leukocytes across endothelial barriers through its interaction with myeloid cells expressing the β2-integrin macrophage receptor 1 (Mac-1) (Rouhiainen et al., 2004). In a static in vitro assay, RAGE was found to bind to the l-domain of Mac-1 with Kd 80–100 nM (Chavakis et al., 2003). Here, our findings may provide another example of how upregulations in brain endothelial RAGE may bind with β2-integrin in EPCs, thus promoting their central accumulation.

In this study, our findings suggest that the ability of reactive astrocytes to promote EPC response may be due to the release of HMGB1. As a damage-associated-molecular-pattern (DAMP) mediator, HMGB1 is traditionally known as a nuclear and cellular danger signal (Lotze & Tracey, 2005). Large elevations in HMGB1 can be deleterious after stroke and brain injury (Kim et al., 2006). However, more recently, it is recognized that HMGB1 can exert different functions depending on its cellular localization. When large amounts are passively released from damaged cells, HMGB1 worsens neuroinflammation and brain injury (Kim et al., 2006). But when lower levels of HMGB1 are actively secreted from reactive astrocytes, beneficial actions can be detected (Hayakawa et al., 2012). Upon release, extracellular HMGB1 binds to its putative receptors (RAGE, TLR2, TLR4), and induces series of signaling pathways in response to the original damage. Recently, we showed that suppressing HMGB1 in reactive astrocytes might worsen neurovascular recovery after focal ischemia in mice (Hayakawa et al., 2010a, 2012). The present study may provide a specific mechanism for this phenomenon that directly links the reactive astrocyte and endothelial cells within the neurovascular unit to a pro-recovery EPC response.

Taken together, our findings support a novel mechanism whereby reactive astrocytes release HMGB1 that upregulates RAGE receptors on brain endothelial cells, thus augmenting β2-integrin-mediated EPC adhesion and transmigration. However, there are several caveats worth keeping in mind. First, we mainly focus on EPCs and we could not detect clear differences in monocytes/macrophages. Recent study demonstrates that TLR4 signaling stimulated by lipopolysaccharide increased microvascular CD200 expression, a cell surface glycoprotein which induces immunosuppressive activity, and CD200 receptor agonist inhibited macrophages interaction to endothelial cells. (Ko et al., 2009) HMGB1 can also stimulate TLR4 in endothelial cells thus the attachment of monocytes/macrophages may not be augmented through CD200 signaling. Nevertheless, how all blood cells interact as they move toward a diseased neurovascular unit remains to be elucidated. Second, other adherence factors and receptors may also contribute. For example, HMGB1 is known to increase expression of vascular cell-adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and endothelial-cell selectin (Lotze & Tracey, 2005; Fiuza et al., 2003). Our focus was on RAGE, but how multiple signals coordinate with multiple receptors in EPCs and endothelium will be a very complicated system that must be further investigated. Third, our in vitro model is limited in its ability to fully replicate in vivo pathophysiology. For example, our models use standard neonatal and very young cell cultures. But of course, disease tends to occur in aged CNS. How our hypothesis of endothelial RAGE and β2-integrin in EPCs contribute to neurovascular remodeling after stroke should be eventually addressed with in vivo studies. Finally, our endpoints are all cell-based and not functional. Whether EPCs has specific phenotype for transmigration is unclear. In addition, during transmigration, EPCs may be stimulated with many factors from both the brain parenchyma and circulating factors in blood thus the phenotype might be changed after transmigration. Future studies should be required to determine the functional sequelae of EPCs that have been amplified by astrocyte-endothelial crosstalk.

Conclusion

The concept of the neurovascular unit, i.e. cell–cell signaling between neuronal, glial and vascular compartments, has provided a powerful framework for investigating the mechanisms of acute injury and delayed recovery after stroke, brain injury and neurodegeneration (Iadecola, 2004; Zlokovic, 2010). This study suggests that signaling at the neurovascular interface may also play a key role in promoting EPC-mediated peripheral responses. By upregulating RAGE on affected endothelial cells, reactive astrocytes may augment EPC adherence and transmigration. This phenomenon may comprise a novel mechanism whereby crosstalk between reactive astrocytes and cerebral endothelium augments EPC responses for neurovascular recovery in damaged or diseased brain. Further studies are warranted to dissect the in vivo consequences of this phenomenon in animal models of stroke, brain injury and neurodegeneration.

Author contributions

KH – study design, experiments, grant support, manuscript writing
LDP — experiments
KA — study design, grant support, manuscript writing
EHL — study design, grant support, manuscript writing

Disclosure of potential conflicts of interest

The authors declare they have no competing financial interest.

Acknowledgment

Supported in part by Rappaport Foundation and NIH (R01-NS6694, R01-NS65089, K99-NS80991).

References

Hori, O., Brett, J., Slattery, T., et al., 1995. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphetamine. Mediation of neurite outgrowth and co-expression of rage and amphetamine in the developing nervous system. J. Biol. Chem. 270, 25752–25761.